Vor Biopharma Inc. (NYSE:VOR) Shares Acquired by Acadian Asset Management LLC

Acadian Asset Management LLC lifted its position in Vor Biopharma Inc. (NYSE:VOR) by 51.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,305 shares of the company’s stock after purchasing an additional 27,597 shares during the period. Acadian Asset Management LLC owned about 0.12% of Vor Biopharma worth $79,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Vanguard Group Inc. lifted its stake in shares of Vor Biopharma by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after purchasing an additional 69,436 shares during the period. Institutional investors own 97.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on VOR. HC Wainwright reiterated a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research note on Friday, September 6th. Barclays decreased their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a research note on Friday, September 6th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $10.92.

Vor Biopharma Stock Performance

Shares of NYSE VOR opened at $0.90 on Friday. The firm has a market cap of $61.43 million, a PE ratio of -0.51 and a beta of -0.34. The firm has a fifty day moving average of $0.93 and a 200 day moving average of $1.39. Vor Biopharma Inc. has a one year low of $0.70 and a one year high of $3.14.

Vor Biopharma (NYSE:VOR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). On average, equities analysts predict that Vor Biopharma Inc. will post -1.51 EPS for the current fiscal year.

Vor Biopharma Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.